Zenas BioPharma, Inc.
ZBIO - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.85B
Close$
$-1.88
106.6% downside
Current Fair Value
106.6% downsideOvervalued by 106.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.85 Billion |
|---|---|
| Enterprise Value | $1.88 Billion |
| Earnings per Share | $-8.44 |
| Beta | -1.02 |
| Outstanding Shares | 63,112,314 |
Return
| Return on Equity | -196.03% |
|---|---|
| Return on Assets | -69.03% |
| Return on Invested Capital | -47.37% |
Valuation & Multiples
| P/E Ratio | -2.95 |
|---|---|
| PEG | -2.6 |
| Price to Sales | - |
| Price to Book Ratio | 7.12 |
| Enterprise Value to Revenue | 1877.59 |
| Enterprise Value to EBIT | -6.23 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 0.91 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$-1.27
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-1.24
Consensus analyst estimateRevenue Estimate
$1.01 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 6.38% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.17%▼ 110.52% |
|---|---|
| Total Invested | $2.84M▼ 99.82% |
| Investors Holding | 13▼ 138.00% |
About Zenas BioPharma, Inc.
130 employees
CEO: Mr. Leon Oliver Moulder Jr., M.B.A.
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibod...